September JAAD: Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phas

AAD's Dialogues in Dermatology - Een podcast door American Academy of Dermatology